Xilio Therapeutics (XLO) Stock Price, News & Analysis

Company Overview

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands. These candidates are designed to selectively accumulate in tumor tissues and activate local innate and adaptive immunity. Xilio has advanced multiple assets into early‐phase clinical studies, evaluating safety, pharmacokinetics and preliminary signals of anti‐tumor activity across various solid tumor types. The pipeline also includes additional preclinical programs that apply the same targeting and activation principles to other cytokine payloads.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Xilio Therapeutics has assembled a management team with deep experience in oncology drug development and biologics engineering. The company conducts its clinical trials primarily in the United States and Europe and collaborates with academic and industry partners to accelerate the translation of its pipeline candidates into potential cancer therapies. Xilio remains committed to advancing its modular cytokine platform to address unmet needs in immuno‐oncology.

Key Stats

• Today's Range: $7.74 to $9.00
• 50-Day Range: $7.16 to $8.81
• 52-Week Range: $6.47 to $16.10
• Volume: 724,706 shs
• Average Volume: 32,617 shs
• Market Capitalization: $52.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.00
• Consensus Rating: Moderate Buy

Xilio Therapeutics Stock Analysis - MarketRank™

Xilio Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 382nd out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Xilio Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Xilio Therapeutics has a consensus price target of $28.00, representing about 217.8% upside from its current price of $8.81.

Amount of Analyst Coverage

Xilio Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Xilio Therapeutics are expected to grow in the coming year, from ($2.39) to $0.36 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xilio Therapeutics is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xilio Therapeutics is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xilio Therapeutics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.94% of the float of Xilio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Xilio Therapeutics has a short interest ratio ("days to cover") of 4.94.

Change versus previous month

Short interest in Xilio Therapeutics has recently decreased by 6.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xilio Therapeutics does not currently pay a dividend.

Dividend Growth

Xilio Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.81

News Sentiment

Xilio Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Xilio Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.45% of the stock of Xilio Therapeutics is held by insiders.

Percentage Held by Institutions

54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 5/14/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XLO
• CIK: 1840233
• Web: www.xiliotx.com
• Phone: 857-524-2466
• Fax: N/A
• Employees: 70
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Xilio Therapeutics: $28.00
• High Price Target: $28.00
• Low Price Target: $28.00
• Potential Upside/Downside: +217.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.04 million
• Net Margins: -58.52%
• Pretax Margin: -58.52%
• Return on Equity: -151.42%
• Return on Assets: -27.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.59
• Quick Ratio: 2.58

Sales & Book Value

• Annual Sales: $43.77 million
• Price / Sales: 1.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.13 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 5,980,000
• Free Float: 5,537,000
• Market Cap: $52.68 million
• Optionable: Not Optionable
• Beta: -0.16